Sea-Buckthorn Seed Oil Induces Proliferation of both Normal and Dysplastic Keratinocytes in Basal Conditions and under UVA Irradiation.
CD36
SR-B2
UVA
long-chain fatty acids
sea-buckthorn seed oil
skin dysplastic keratinocytes
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
07 Apr 2021
07 Apr 2021
Historique:
received:
16
03
2021
revised:
01
04
2021
accepted:
04
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Past decades demonstrate an increasing interest in herbal remedies in the public eye, with as many as 80% of people worldwide using these remedies as healthcare products, including those for skin health. Sea buckthorn and its derived products (oil; alcoholic extracts), rich in flavonoids and essential fatty acids, are among these healthcare products. Specifically, sea buckthorn and its derivatives are reported to have antioxidant and antitumor activity in dysplastic skin cells. On the other hand, evidence suggests that the alteration of lipid metabolism is related to increased malignant behavior. Given the paradoxical involvement of lipids in health and disease, we investigated how sea-buckthorn seed oil, rich in long-chain fatty acids, modifies the proliferation of normal and dysplastic skin cells in basal conditions, as well as under ultraviolet A (UVA) radiation. Using real-time analysis of normal and dysplastic human keratinocytes, we showed that sea-buckthorn seed oil stimulated the proliferation of dysplastic cells, while it also impaired the ability of both normal and dysplastic cells to migrate over a denuded area. Furthermore, UVA exposure increased the expression of CD36/SR-B2, a long-chain fatty acid translocator that is related to the metastatic behavior of tumor cells.
Identifiants
pubmed: 33917064
pii: jpm11040278
doi: 10.3390/jpm11040278
pmc: PMC8067731
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii
ID : P_40_197/2016
Organisme : Ministry of Research and Innovation
ID : PN 19.29.01.04.
Références
J Invest Dermatol. 2002 Jul;119(1):22-6
pubmed: 12164919
Front Pharmacol. 2018 Mar 15;9:232
pubmed: 29593547
J Patient Exp. 2017 Sep;4(3):108-113
pubmed: 28959715
Biochim Biophys Acta. 2014 Mar;1841(3):362-8
pubmed: 24120574
Exp Dermatol. 2013 Oct;22(10):677-9
pubmed: 24079743
Dis Model Mech. 2013 Nov;6(6):1353-63
pubmed: 24203995
Antioxidants (Basel). 2018 Aug 23;7(9):
pubmed: 30142919
J Dermatol Sci. 2018 Dec;92(3):254-263
pubmed: 30522882
Biochim Biophys Acta. 2011 Aug;1812(8):1007-22
pubmed: 21382489
Med Sci Monit Basic Res. 2015 Apr 30;21:86-95
pubmed: 25925725
J Clin Invest. 2012 Feb;122(2):464-72
pubmed: 22293185
J Biol Chem. 2002 May 3;277(18):15703-11
pubmed: 11867619
Lipids Health Dis. 2017 May 19;16(1):95
pubmed: 28526097
Front Pharmacol. 2014 Jan 10;4:177
pubmed: 24454289
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
Tumour Biol. 2014 Oct;35(10):9563-9
pubmed: 24957042
Int J Mol Sci. 2018 Jun 07;19(6):
pubmed: 29880745
Anal Quant Cytol Histol. 2009 Feb;31(1):17-25
pubmed: 19320189
Front Immunol. 2019 Oct 18;10:2416
pubmed: 31681304
PLoS One. 2012;7(4):e34099
pubmed: 22558083
Immunology. 2018 Jan;153(1):97-104
pubmed: 28815581
Fitoterapia. 2009 Apr;80(3):164-7
pubmed: 19535023
J Dermatol. 1996 May;23(5):305-9
pubmed: 8675818
J Am Acad Dermatol. 2013 Jan;68(1 Suppl 1):S10-9
pubmed: 23228301
Evid Based Complement Alternat Med. 2015;2015:765705
pubmed: 26421051
Nature. 2017 Jan 5;541(7635):41-45
pubmed: 27974793
J Cutan Pathol. 1991 Jun;18(3):198-203
pubmed: 1717527
Biomed Res Int. 2018 Jul 4;2018:7801202
pubmed: 30069479
J Biol Chem. 2005 Feb 18;280(7):5636-45
pubmed: 15533929
PLoS Pathog. 2009 Jul;5(7):e1000527
pubmed: 19629174
Int J Mol Sci. 2012 Dec 06;13(12):16718-36
pubmed: 23222638